NY-ESO-1 T cells are genetically modified T cells that are re-infused into the patient. It is being developed for the treatment of cancers including melanoma, multiple myeloma and synovial sarcoma. It is currently in Phase III clinical trials.
NY-ESO-1 T cells for the treatment of synovial sarcoma
Interventions:
NY-ESO-1c259-modified SPEAR T Cells (GSK3377794)
Indications:
Soft tissue sarcoma
Therapeutic Areas:
Sarcoma
Year:
2017